Celsion Corp.
997 Lenox Drive
Suite 100
Lawrenceville,
NJ 08648
United States - Map
Phone: 609-896-9100
Fax: 609-896-2200
Website: http://www.celsion.com
Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under Phase III clinical trial for primary liver cancer; under phase II clinical trial for colorectal liver metastasis; and under phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. for ThermoDox; and a joint research agreement with Royal Philips Electronics to evaluate the combination of Philips' high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat various cancers. The company was founded in 1982 and is based in Lawrenceville, New Jersey. Key Statistics
| |
| | Pay | Exercised | Mr. Michael H. Tardugno ,
62
Chief Exec. Officer, Pres and Director | 679.00K | 0.00 | Mr. Gregory L. Weaver CPA, M.B.A,
57
Chief Financial Officer and Sr. VP | 369.00K | 0.00 | Mr. Jeffrey W. Church CPA,
56
Sr. VP of Corp. Strategy and Investor Relations | 353.00K | 0.00 | Dr. Nicholas Borys M.D.,
54
Chief Medical Officer and VP | 379.00K | 0.00 | Dr. Alberto R. Martinez M.D.,
63
Director, Member of Nominating & Governance Committee and Member of Compensation Committee | 35.00K | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.07(7.44%) May 17, 4:00PM EDT|After Hours
:
1.01 0.00 (0.00%) May 17, 7:58PM EDT